1. Home
  2. CCM vs SYBX Comparison

CCM vs SYBX Comparison

Compare CCM & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concord Medical Services Holdings Limited

CCM

Concord Medical Services Holdings Limited

N/A

Current Price

$3.74

Market Cap

23.8M

Sector

Health Care

ML Signal

N/A

Logo Synlogic Inc.

SYBX

Synlogic Inc.

HOLD

Current Price

$1.42

Market Cap

20.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCM
SYBX
Founded
1997
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.8M
20.0M
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
CCM
SYBX
Price
$3.74
$1.42
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.0K
32.2K
Earning Date
09-26-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$51,056,841.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.60
$0.90
52 Week High
$10.77
$1.96

Technical Indicators

Market Signals
Indicator
CCM
SYBX
Relative Strength Index (RSI) 33.78 28.45
Support Level $3.71 $1.58
Resistance Level $4.00 $1.73
Average True Range (ATR) 0.21 0.09
MACD -0.03 -0.03
Stochastic Oscillator 10.68 5.77

Price Performance

Historical Comparison
CCM
SYBX

About CCM Concord Medical Services Holdings Limited

Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Share on Social Networks: